Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
Industry Veteran with Business Development and Transactional Expertise Joins Eiger Board of Directors
Eiger BioPharmaceuticals, Inc. announced the appointment of Paul Truexto its Board of Directors.
Truex is the founder, President and CEO of Anthera Pharmaceuticals - a private pharmaceutical company focused on the development of anti-inflammatory products for life threatening cardiovascular and pulmonary diseases. Previously he was Founder, President and CEO of Peninsula Pharmaceuticals where he negotiated both of Peninsula's anti-infective product agreements with Shionogi & Co. Ltd. and Takeda Chemical Industries respectively. Peninsula was acquired by Johnson & Johnson in 2005 for US$ 245 million. Previously, Mr. Truex held positions at Versicor (Vicuron), which was acquired by Pfizer for US$ 1.9 billion, and at Eli Lilly. Mr. Truex obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.